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Available online 21 January 2012AbstractBackground: The aim of this study was to assess possible risk factors for urinary leakage of a newly formed urinary conduit after a partial or
total pelvic exenteration.
Methods: An analysis was conducted from prospectively collected data of patients who underwent a pelvic exenteration with conduit for-
mation for advanced and recurrent pelvic cancer.
Results: Of 232 patients undergoing a pelvic exenteration, 74 (32%) had a conduit formed. Of these, 47 (64%) had an ileal conduit com-
pared with 27 (36%) a colonic conduit. Twelve (16%) patients developed a leak, of which nine occurred within the first month. Factors
associated with a conduit leak included involvement of R2 surgical margins (43%), the magnitude of the exenteration and a current car-
diovascular medical history (27%). Leaks were not found to be associated with either radiotherapy or chemotherapy. The 30-day leak rate
for ileal conduits was 17% (8/47) and 4% (1/27) for colonic conduits with enterocutaneous fistula only occurring in the ileal conduit group
(2/47). Fistula, drained collections and sepsis occurred in 40% of ileal and 19% of colonic conduits ( p < 0.01). Patients with a conduit leak
had a longer length of stay (59 versus 23 days, p < 0.001).
Conclusions: Urine leaks after conduit formation in association with exenterations are relatively common with a prolonged length of hos-
pital stay. Positive surgical margins and exenterations involving all four quadrants of the pelvis were associated with higher leak rates.
There was no evidence of a difference between ileal and colonic conduits and number of leaks. However colonic conduits had less total
complications including sepsis, leak and pelvic collections with comparatively no complications of a small bowel fistula.
 2011 Elsevier Ltd. All rights reserved.
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Total pelvic exenteration is used for the resection of lo-
cally advanced and recurrent pelvic tumours.1 Long term
survival with good local control is possible,2e5 however
morbidity is high after surgery with rates reported between
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doi:10.1016/j.ejso.2011.12.002Where the cancer invades the bladder (or prostate or
when the bladder is neuropathic after saccrectomy) pelvic
exenteration involves removal of the bladder, requiring
the urinary flow to be redirected. As a general principle,
any segment of bowel can be used to form a urinary diver-
sion10,11 but usually a segment of ileum is used to create the
conduit. More recently, the established colostomy after
a previous abdominoperineal resection has been utilised
as the preferred conduit in recurrent rectal cancer particu-
larly if the terminal ileum is grossly damaged by radiother-
apy. The conduit is based on the middle colic artery and the
more proximal transverse colon is transected and brought
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cludes the use of irradiated ileum for the conduit and the
need for a small bowel anastomosis after harvest of the ileal
conduit. Complications related to urinary conduits however
are frequent9,12,13 and therefore prone to re-intervention14
which results in prolonged hospital stay and increased med-
ical costs.
A number of pre-operative prognostic factors have been
explored for conduits leaks, for example vascular co-
morbidity, however no significant evidence has been found
to date.15,16 Therefore the objectives of this paper were to ret-
rospectively audit the incidence of urinary conduit leaks post
pelvic exenteration and to investigate whether patient or clin-
ical characteristics, including the choice of a colonic rather
than an ileal conduit, were predictive of this adverse outcome.
MethodsPatient samplePatients were eligible if they were admitted to Royal
Prince Alfred Hospital, Sydney between December 1995
and December 2010 with an advanced or recurrent pelvic tu-
mour and underwent complete pelvic exenteration surgery.
Patients were pre-operatively assessed and selected using
CT, MRI and PET-scanning17 in order to either rule out, or
establish, bladder involvement and to screen for distant me-
tastases. Cases were then discussed at a multi-disciplinary
meeting which included colorectal surgeons and urologists.Description of surgeryDuring complete (bowel and urine) exenteration surgery,
patients underwent either a (1) anterior and central exenter-
ation (excision of the bladder and part of rectum or neorec-
tum), (2) anterior, central and lateral exenteration (anterior
and central with excision of lateral neurovascular structures
always including internal and occasionally external iliac
vessels), (3) anterior, central and posterior exenteration (an-
terior and central with a saccrectomy) or (4) total exenter-
ation (anterior, central, lateral and posterior).18 All
exenterations involved excision of the infra and supra leva-
toric compartments. Subsequently an ileal or colonic con-
duit was formed as high up in the ureter out of the
irradiated field as technically possible. Initially, a urinary
conduit was only formed using the colon if the ileum was
unsuitable for a safe anastomosis due to radiotherapy dam-
age. This excluded the need for an entero-enterostomy in
the radiated small bowel therefore potentially lowering
the ureteric to conduit leak rates. Progressively over time,
the colonic conduit became the preferred conduit when
an established colostomy was present. After the exentera-
tion the “Bricker technique” was used to form the conduit,
leaving behind two catheters to rest the newly formed su-
tures. All complications were recorded in a prospective
database.Data collectionData were retrieved from the prospective database and
confirmed with surgical case files, electronic and paper hos-
pital medical records. The number of conduit leaks were
confirmed and extracted from CT reports along with gen-
eral patient characteristics from case files and medical re-
cords (age, gender, length of hospital stay), pre-operative
factors (cardiovascular illness, radiotherapy, chemother-
apy), characteristics of the cancer (primary, recurrent, re-
recurrent presentation), peri-operative variables (type of ex-
enteration, type of conduit) and post-operative risk factors
(surgical margins). Completeness of resection was defined
as R0 (complete resection of tumour), R1 (microscopic tu-
mour remnant at circumferential margin) and R2 (macro-
scopically involved margin, usually performed for
palliation). Patients who received radiotherapy were cate-
gorised into one of three groups, either neo-adjuvant (ther-
apy received before current exenteration) or prior
radiotherapy received within past two years or received
more than two years for the initial primary or another pel-
vic tumour/operation. Finally the date of last contact, and if
applicable, the date and reason of death where recorded
was extracted. This data item was provided by periodic up-
dates from the state-wide registry of births and deaths.Statistical analysisThe associations between the patient demographics, clini-
cal characteristics and the outcome of a conduit leak were ex-
amined using two fixed follow-up periods; within 30-days
following surgery and in first threemonths. Thirty day compli-
cations were thought to reflect direct surgical complications
whilst three month follow-up included surgical plus early dis-
ease failure. Statistical analysis was performed by using
STATA version 11.1. Fisher’s exact test was used to test for
any association between thegroups and the outcome at the uni-
variate level. A univariate log-rank test was conducted to test
for any relationship between a conduit leak and the probability
of death. This test uses survival analysis methods, where pa-
tients were censored at their most recent known date of fol-
low-up. Ethics approval was established from Sydney Local
Health District (RPAH Zone) for this study to be completed.
ResultsStudy sample: overviewDuring the study period 232 patients underwent a pelvic
exenteration. Seventy four patients (32%) had a conduit
formed as part of the procedure. The tumour characteristics
of these patients were varied including rectal (50), colonic
(5), anal SCC (7), pelvic SCC (3), cervical (2), vulvo-
vaginal (2), uterine (1), ovarian (1), prostate (1), perianal
melanoma (1) and embryologic rhabdomyosarcoma (1).
Demographic and clinical characteristics of these patients
363S.C. Teixeira et al. / EJSO 38 (2012) 361e366are displayed in Table 1. The mean age of patients was 59
years (range 14e91) and 74% were males. All patients had
a complete pelvic exenteration (bladder and bowel) with
57% a saccrectomy and 40% dissection of the lateral com-
partment including resection of the internal iliac vascula-
ture.18 Of these 75 patients, 25 exenterations involved the
anterior and central quadrants of the pelvis, 7 the anterior,
central and lateral quadrants, 20 the anterior central and
posterior quadrants and 22 a total pelvic exenteration. In to-
tal 65 (88%) patients had received pre-operative radiother-
apy either at initial primary resection (54%) or as neo-
adjuvant to the exenteration (33%).Table 1
Characteristics of patients and urinary leaks observed in a fixed 30-day pe-
riod following surgery.
Patient characteristics n (%) all
patientsa
n (%) patients
with leaksb
p-value
(Fisher’s)
Age 0.42
<70 years 57 (77) 6 (11)
70 years 17 (23) 3 (18)
Sex 0.69
Male 55 (74) 6 (11)
Female 19 (26) 3 (16)
Radiotherapy 1.00
Yes 65 (88) 8 (12)
No 9 (12) 1 (11)
Timing of radiotherapy 0.95
No radiotherapy 9 (13) 1 (11)
Neo-adjuvant for
current exenteration
24 (33) 2 (8)
Prior radiotherapy
 2 yearsc
26 (36) 3 (12)
Prior radiotherapy
> 2 yearsc
13 (18) 2 (15)
Chemotherapy 0.26
Yes 53 (72) 5 (9)
No 21 (28) 4 (19)
Cardiovascular MH 0.08
Yes 15 (20) 4 (27)
No 59 (80) 5 (8)
Surgical margins 0.05
R0 52 (70) 5 (10)
R1 15 (20) 1 (7)
R2 7 (10) 3 (43)
Presentation of cancer 1.00
Primary 18 (24) 2 (11)
Recurrent 47 (64) 6 (13)
Re-recurrent 9 (12) 1 (11)
Type of conduit 0.14
Ileal 47 (64) 8 (17)
Colonic 27 (36) 1 (4)
Type of exenteration 0.08
Anterior and central 25 (34) 1 (4)
Anterior, central, lateral 7 (9) 1 (14)
Anterior, central, posterior 20 (27) 1 (5)
Anterior, central,
posterior, lateral
22 (30) 6 (27)
a Data are numbers with percentages in parentheses unless otherwise
indicated.
b Data are numbers and percentages of patients with a leak within each
category.
c Radiotherapy for initial primary or another pelvic tumour operation.Urological leaks and type of conduitPatient and clinical factors associated with a urological
leak at 30-days are shown in Table 1. An ileal conduit
was formed in 47 patients with the remaining 27 patients
receiving a colonic conduit. There were no statistically sig-
nificant differences in leak rates between conduit groups at
30-day (17% versus 4%; p ¼ 0.14) or 90-day (19% versus
11%; p ¼ 0.52). Other potential patient and clinical associ-
ations with a leak and conduit type are presented in Table 2.Patient and clinical associations with urological
leaksSurgery involving the anterior, central, posterior and lat-
eral compartments of the pelvis total had the highest leak
rates. Six (27%) developed a leak by 30-days post-
operatively with a total of eight (36%) by 90-days. Patients
who underwent this extensive surgical procedure were sig-
nificantly more likely ( p ¼ 0.02) to develop a leak within
90-days compared to other types of exenterations. Patients
with a macroscopic involved margin (R2) were found to
have a significantly higher conduit leak rate at 30-days
compared to those with a clear (R0) or microscopically
(R1) involved margin ( p ¼ 0.05). Patients with a macro-
scopically involved margin R2 had a 43% leak rate com-
pared to 7% and 15% for R1 and R0 margins at 90-days.
Receiving any radiotherapy was not found to be a signif-
icant predictor of a leak at either time point. Also the tim-
ing of radiotherapy, either current or prior radiotherapy
more of less than two years ago was also found to not pre-
dict a urological leak. Similarly the use of current or prior
chemotherapy was not found to influence the development
of a conduit leak at either 30 or 90-days. There was a weak
statistical association ( p ¼ 0.08) between a current cardio-
vascular illness (i.e. active treatment) at the time of surgery
and an adverse conduit outcome. Presentation of cancer i.e.
advanced primary, recurrent or re-recurrent was not found
to significantly influence the risk of a leak.Impact of urological leaks on hospital length of stay
and survivalLength of stay was significantly higher for patients with
a conduit leak (59 days versus 23 days; p < 0.001). An ad-
verse relationship between the development of a conduit
leak and survival was also found in this cohort (Table 3).Surgical morbidityTable 4 reports the incidence of major complications by
conduit group. There were two small bowel enterocutane-
ous fistulae in the ileal and none in the colonic conduit
group. When the incidence of all complications potentially
related to the conduits were considered (i.e. grouping all
leaks, fistulae, defined septic events and percutaneously
Table 2
Characteristics of patients and who underwent a pelvic exenteration with
a colonic or ileal conduit.a
Type of conduit
Patient characteristics Ileal (n-47) Colonic (n-27) p-value
Age (years) e Mean (SD) 61.4 (15.1) 55.7 (9.9) 0.08
Median (Range) 59.7
(14.3e91.3)
53.7
(39.8e74.3)
Age 0.02
<70 years 32 (68) 25 (93)
70 years 15 (32) 2 (7)
Sex 0.55
Male 36 (77) 19 (70)
Female 11 (23) 8 (30)
Radiotherapy 0.34
Yes 40 (85) 25 (93)
No 7 (15) 2 (7)
Timing of radiotherapyb 0.71
No radiotherapy 7 (15) 2 (8)
Neo-adjuvant for
current exenteration
15 (32) 9 (35)
Prior radiotherapy  2 yearsc 15 (32) 11 (42)
Prior radiotherapy > 2 yearsc 9 (20) 4 (15)
Chemotherapy 0.72
Yes 33 (70) 20 (74)
No 14 (30) 7 (26)
Cardiovascular MH 0.14
Yes 12 (26) 3 (11)
No 35 (74) 24 (89)
Surgical margins 0.63
R0 34 (72) 18 (67)
R1 8 (17) 7 (26)
R2 5 (11) 2 (7)
Presentation of cancer 0.04
Primary 15 (32) 3 (11)
Recurrent 29 (62) 18 (67)
Re-recurrent 3 (6) 6 (22)
Type of exenteration 0.08
Anterior and central 17 (36) 8 (30)
Anterior, central, lateral 5 (11) 2 (7)
Anterior, central, posterior 10 (21) 10 (37)
Anterior, central,
posterior, lateral
15 (32) 7 (26)
Previous pelvic operation 0.37
Yes 30 (64) 20 (74)
No 17 (36) 7 (26)
a Data are numbers with percentages in parentheses unless otherwise in-
dicated. Where data do not to add to 100% is due to rounding.
b n ¼ 2 missing.
c Radiotherapy for initial primary or another pelvic tumour operation.
Table 3
Conduit leak with number of deaths, median survival time and p-values
from log-rank test.
Patient
characteristic
Number of
patientsa
Number of
deathsb,c
Median
survival time
(months)
Log-rank p-value
Conduit leak
Yes 12 (16) 4 33.6
No 62 (84) 20 40.2 0.04
a Data are numbers with parentheses in parentheses unless otherwise
indicated.
b Data are the number of deaths within each category.
c No mortality was reported within the first 30-day post-operatively.
Maximum follow-up was 142 months.
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found between the ileal and colonic groups (40% versus
19%; p < 0.001).Table 4
Complications by type of conduit at 30-day.
Ileal conduit Colonic conduit p-valueDiscussion
n ¼ 47 n ¼ 27
Urinary leaks 8 (17) 1 (4) 0.14
Small bowel fistula 2 (4) 0 (0) 0.53Patient and clinical associations with urological
leaksSepsis 4 (9) 4 (15) 0.45
Drained collections 5 (11) 0 (0) 0.15
Total complications 19 (40) 5 (19) <0.01
Surgical treatment for locally advanced and recurrent
pelvic tumours is increasingly being managed using totalpelvic exenteration. Where tumours invade the bladder
a urinary conduit is formed, however these can result in
a range of urological complications which can require re-
intervention resulting in patient morbidity, prolonged hos-
pital stay and thus increased medical costs. This study
has identified a number of risk factors for conduit leaks in-
cluding the magnitude of the exenteration and whether
macroscopically involved margins were present. At three
months, a significant relationship between the type of sur-
gery and risk of a conduit leak was found. Specifically,
the more extensive the surgical procedure (i.e. saccrectomy
and/or excision of the lateral neurovascular structures), the
greater the risk of a conduit leak. This finding is not surpris-
ingly and has also been found to be associated with an in-
creased number of morbidities following pelvic
exenteration with saccrectomy and also with lateral com-
partment dissection.18
The long hospital stay with a conduit leak has significant
financial implications for this complication. The magnitude
of the surgery may account for part of this association as
does the extent of disease.19 Without a macroscopically
clear margin a higher rate of conduit leaks was found. Pos-
itive margins in our series of recurrent rectal cancers have
shown to be the dominant predictive factor for decreased
five year survival as well as the strongest predictor of
poorer quality of life.20,21 This highlights the importance
of achieving a clear margin whenever possible. However,
for patients with extensive or disseminated disease within
the pelvis, achieving this is not always technically possible.
The pathological involved margin (R1) was not signifi-
cantly higher compared with the clinically involved margin
(R2). This finding reinforces that palliative exenterations
have the highest morbidity.
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colonic conduits and the number of urological leaks but an
increased risk of potential complications was seen in the il-
eal group. Clinically, this suggests that as the colon is not
damaged by pre-operative radiotherapy, a colonic conduit
can safely be formed which could confer the advantage
of using the already established stoma for the formation
of the urinary conduit. Secondly, no small bowel fistulae
were recorded in the colonic conduit group compared to
the ileal conduit group. Combining the major morbidity po-
tentially associated with conduits (fistulae, leaks, collec-
tions drained and confirmed septic episodes) there was
significantly more in the ileal conduit group compared
with the colonic group. This finding has not been reported
previously and suggests that colonic conduits may be as
safe as ileal conduits without the risks of fistula and perhaps
diminishing the subsequent potential nutritional deficit with
removing a segment of ileum in radiotherapy damaged
small bowel as well as fistula.Other potential risk factors for urological leaksVascular compromised patients are known to have
poorer tissue healing which results in higher rates of anas-
tomotic leaks. A cardiovascular medical history has been
shown to be a significant predictor of post-operative com-
plications for people undergoing a curative anterior resec-
tion.22 Bertelsen et al22 has reported that this risk is
significantly increased for patients who are smokers (OR
1.88, CI 1.02e3.46). The current study has shown weak ev-
idence of a relationship between a currently treated cardio-
vascular condition and a conduit leak. The choice of
palliative exenterations in combination with current cardio-
vascular risk factors may be a relative contraindication for
future patients if confirmed in larger series.
Other known possible risk factors for conduit leaks such
as age and radiotherapy were not found to play a significant
role in this type of complication in this cohort. Although
Stotland et al23 demonstrated that the rate of urologic com-
plications was similar in patients who had received radia-
tion prior to the index surgery compared to those who
had not there are a number of other studies suggesting
that these therapies in the pre and post-operative setting
are likely to increase the risk of urological complications.24
For example, Russo et al.25 have reported a urologic com-
plication rate of 17% after peri-operative chemoradiation
for recurrent rectal cancer, whilst Angioli et al.24 noted
that 35% of the irradiated patients developed anastomotic
breakdown or fistulae compared to only 7.5% of patients
in the non-irradiated group. In the current study, the almost
universal prior use of radiotherapy (88%) and chemother-
apy (72%) did not allow a large comparative cohort of
non-treated patients meaning that these therapies may still
be the cause of the high urological complication rates. Alarger study would be required with a higher proportion
of people who did not receive radiotherapy or chemother-
apy to investigate these factors further.Urological leaks and survivalAlthough the groups compared do not consist of large
numbers, a survival disadvantage was found for patients
who were affected by a conduit leak following a pelvic ex-
enteration. However care should be taken in interpretation
particularly given that the prevalence of conduit leaks are
higher in those patients with the shortest follow-up time
in this cohort as well as having a greater magnitude of
exenteration.Study limitationsThis study presents 15 years of data. Whilst many surgi-
cal techniques have changed over this time period, the key
change in pelvic exenteration surgery would have been
a more radical approach to tumour resection given that in-
ternational data has supported a survival benefit of this ap-
proach over the past decade.18,21 It should also be noted
that the majority of the patients in this cohort (88%) had
their exenterations performed within the last five years by
one surgeon, or under the supervision of one surgeon. It
is likely in this study that colonic conduits were more likely
to be used in those patients with the greatest radiotherapy
damage to the small bowel as this was the only initial indi-
cation for colonic conduits. The increased utilisation elec-
tively rather than selectively of ileal versus colonic
conduits in all patients undergoing complete exenterations
may reveal an even lower comparative leak rate. Ongoing
multicentre collaboration of data and eventually prospec-
tive trials will be required to answer these vexing questions.
The use of “wet” colostomies is a third option yet to be
fully assessed (i.e. urine and faeces through one ostomy).
Conclusion
This study suggests that urological complications after
pelvic exenteration are relatively common resulting in pro-
longed hospital length of stays. The type of urological con-
duit formed was not found to be significantly associated
with the risk of a leak but with an increase in potential con-
duit related complications. The effect of radiotherapy can-
not readily be assessed in this study, however
macroscopically involved margins and exenterations in-
volving all four quadrants of the pelvis have the highest in-
cidence of leaks.
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